Aletheian Wealth Advisors LLC Sells 5,426 Shares of Johnson & Johnson (NYSE:JNJ)

Aletheian Wealth Advisors LLC decreased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 72.8% during the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 2,032 shares of the company’s stock after selling 5,426 shares during the quarter. Aletheian Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $329,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. Mirador Capital Partners LP boosted its stake in Johnson & Johnson by 4.2% during the first quarter. Mirador Capital Partners LP now owns 20,508 shares of the company’s stock worth $3,244,000 after buying an additional 833 shares in the last quarter. Aviance Capital Partners LLC boosted its position in shares of Johnson & Johnson by 63.3% during the 1st quarter. Aviance Capital Partners LLC now owns 37,818 shares of the company’s stock valued at $5,982,000 after acquiring an additional 14,663 shares in the last quarter. Skyline Advisors Inc. increased its stake in Johnson & Johnson by 3.5% in the first quarter. Skyline Advisors Inc. now owns 2,478 shares of the company’s stock valued at $392,000 after acquiring an additional 83 shares during the period. Wolff Wiese Magana LLC raised its position in Johnson & Johnson by 8.0% in the first quarter. Wolff Wiese Magana LLC now owns 3,950 shares of the company’s stock worth $625,000 after purchasing an additional 294 shares in the last quarter. Finally, BKM Wealth Management LLC lifted its stake in Johnson & Johnson by 16.3% during the first quarter. BKM Wealth Management LLC now owns 14,473 shares of the company’s stock worth $2,289,000 after purchasing an additional 2,025 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Stock Up 0.3 %

NYSE:JNJ opened at $160.62 on Thursday. The company has a market cap of $386.56 billion, a price-to-earnings ratio of 10.01, a P/E/G ratio of 2.90 and a beta of 0.52. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.85 and a current ratio of 1.07. The stock’s fifty day moving average price is $163.44 and its two-hundred day moving average price is $155.32. Johnson & Johnson has a 52-week low of $143.13 and a 52-week high of $168.85.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.21 by $0.21. The business had revenue of $22.47 billion for the quarter, compared to analysts’ expectations of $22.17 billion. Johnson & Johnson had a return on equity of 35.46% and a net margin of 19.14%. The firm’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same quarter last year, the business earned $2.66 earnings per share. On average, analysts anticipate that Johnson & Johnson will post 9.94 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th will be issued a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, November 26th. This represents a $4.96 annualized dividend and a yield of 3.09%. Johnson & Johnson’s dividend payout ratio is currently 30.92%.

Insiders Place Their Bets

In other news, VP Robert J. Decker sold 5,635 shares of the stock in a transaction on Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the transaction, the vice president now owns 18,973 shares of the company’s stock, valued at $3,131,683.38. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on JNJ shares. Morgan Stanley increased their target price on Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 16th. TD Cowen cut their price objective on Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating for the company in a report on Thursday, July 18th. Wells Fargo & Company boosted their target price on shares of Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 16th. TD Securities cut their price target on shares of Johnson & Johnson from $195.00 to $185.00 in a report on Thursday, July 18th. Finally, StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, September 14th. Six equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $175.93.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.